July 6, 2022 – ViroBlock, a startup company founded by Hebrew University of Jerusalem (HU) researchers, developed a new drug platform for rapidly generating anti-viral drugs that target proteins common to all viruses.
“Currently, there are no efficient, validated platforms for rapidly generating anti-viral drugs,” says ViroBlock CEO and Founder Isaiah (Shy) Arkin, who is also an HU professor of biological chemistry at the Alexander Silberman Institute of Life Sciences. “Scientists must develop new agents and a customized approach to target every new virus, without the ability to predict how that virus will develop resistance. ViroBlock is working on a promising drug candidate for COVID-19 using an approach that can be duplicated with most other important viruses.”
According to a new study conducted by pharma research company Evotec, ViroBlock’s new technology platform demonstrated the potential to rapidly provide solutions for treating current and emerging viral threats, including COVID-19 and variants, influenza, Zika, West Nile, and Hepatitis B. The study showed that channel blockers it identified could protect cells from viral-induced death alongside dramatically lowering the amount of viral progeny.
ViroBlock’s antiviral drug candidates inhibit two targets in the virus: the E (envelope) protein and the 3a protein. The E protein is an ion channel, a type of protein family expressed by virtually all living cells that because of its structure has served as a frequent target for pharmaceutical point interventions. For example, while the spike proteins of SARS-CoV-2 and SARS-CoV-1 (the 2003 virus) are only about 75% identical, their E proteins are roughly 95% alike. This means the ViroBlock drugs would likely remain effective even when the virus mutates.
“With our propriety technology, ViroBlock can identify targets in a new viral threat (or variant), develop inhibitors against it, and determine the resistance potential of the virus against the new drug, all at an unprecedented pace,” Arkin says.
The next phase of clinical trials will test the efficacy of this anti-viral approach for humans. The company also has drugs in the pipeline produced by the platform currently being tested that could be effective against other viruses.
ViroBlock was founded in 2020 by Yissum, the Hebrew University technology transfer company.
Related articles
Disease-Resistant Carp: Enhancing Gefilte Fish Quality
April 18, 2024 — According to a new study led by Prof. Lior David from the Faculty of Agriculture at the Hebrew University of Jerusalem focusing on the common carp—a widely produced fish in the aquaculture industry and often the main ingredient in the Passover dish, gefilte fish—selective
New Approach that Reveals the Evolution of Ancient Ocean Oxygenation Developed by Hebrew University and U.S. Researchers
April 12, 2024 — A new approach to reconstruct the increase of oxygen in ancient marine environments using Uranium-lead (U-Pb) dating of dolomite rocks to detect signals of oxygenation has been developed by a team of researchers led by the Hebrew University of Jerusalem. The findings have
New Drug Delivery System Developed by Hebrew University Researchers Simultaneously Delivers Diverse Therapeutic Agents in a Single Carrier
April 12, 2024 — A new drug delivery system that overcomes previous limitations in delivering diverse therapeutic compounds in a single carrier has been developed by Hebrew University of Jerusalem researchers. According to the new study published in Cell Press, the innovative drug delivery system
